Montreal, Canada
Repare Therapeutics, founded in 2016, is a prominent player in the precision oncology sector, based in Canada. The company utilizes a proprietary synthetic lethality approach to develop innovative cancer therapies. Their SNIPRx® platform, powered by genome-wide CRISPR technology, targets genomic instability, including DNA damage repair, to create highly specific oncological treatments.
Positioned as a leader in the Biotechnology and Pharmaceutical industries, Repare Therapeutics works closely with renowned academics to leverage their insights into synthetic lethality. This strong foundation promises a strategic edge in the development of new precision oncology medicines.
The company's last recorded financial activity involved a substantial $101.20M growth equity investment on 01 February 2026. The nature of this investment highlights the market confidence in their strategic direction and innovative potential.
Investors should note Repare's commitment to safety and integrity, warning against fraudulent recruiting activities and emphasizing their rigorous communication protocols.